Sehrish Khurshid1, Rabbia Tariq2, Javeria Qureshi3, Raffia Mazher4
1Department of Pathology, Hamdard University.2Department of Pathology, Isra University. 3Department of Hematology, Sindh Institute of Urology and Transplantation, 4Department of Nephrologhy, Liaquat University of Medical and Health Sciences.
Objective: To determine the prevalence of altered thrombophilia in chronic kidney disease.
Study Design: Descriptive retrospective study
Place and duration of study: The study was conducted at Isra University hospital from June 2019 to December 2020
Material and Methods: 150 patients of stage 3, 4 and 5 of chronic kidney disease were enrolled in the study. Patients with stage 1 and 2 chronic kidney disease and on anticoagulation treatment were excluded from study. Stages of chronic kidney disease were classified according to KDIGO criteria. Thrombophilia screening for Antithrombin-III, protein C, protein S, Lupus anticoagulant and Activated Protein C was performed on coagulation analyzer. Findings were recorded and data were analyzed by SPSS version 25
Results: Fifty Seven out of 150 patients were positive for thrombophilia screening with Antithrombin-III deficiency in 28.3%, Protein C deficiency in 7.9%, Protein S deficiency in 3.3%, Lupus anticoagulant in 6.6% and activated Protein C resistance in 2.0%. Out of 43 Antithrombin-III deficient patients, 53.4% (n=23) were on hemodialysis. Out of 12 Protein C deficient patients, 58.3 %(n=7) were on hemodialysis. Out of 10 patients with lupus anticoagulant, 60% (n=6) were on hemodialysis and out of 3 patients with Activated Protein C resistance, 33.3% (n=1) were on hemodialysis.
Conclusion: In this study, Antithrombin-III deficiency was most common finding in CKD and thrombophilia was most common in stage 5 chronic kidney disease and lupus anticoagulant was common finding in relation to hemodialysis. More studies are needed to define true significance of thrombophilia screening in all stages of CKD patients.